News
-
-
-
Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
2020-10-05
-
-
-
-
Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at CSCO 2020
2020-09-22
-
-
-
-
Opening of Hauck Investment Management (Shanghai) Co.
2020-09-22
-
-
-
-
Facilitating an Organisational Upgrade and Capitalising on European Opportunities
2020-09-21
-
-
-
-
WHO Adds Fosun Pharma’s Covid-19 Test to Its Emergency Use List
2020-09-11
-
-
-
-
Fosun successfully held FC2M Conference to expedite further industry operations development
2020-09-09
-
-
-
-
Fosun International’s HSI ESG rating upgraded, Selected as constituent of Hang Seng Corporate Sustainability Benchmark Index
2020-09-07
-
-
-
-
Fosun International improves MSCI ESG rating to grade A
2020-09-03
-
-
-
-
Fosun International Announces 2020 Interim Results Total revenue reaches RMB63.27 billion, demonstrating a rapid business recovery
2020-08-27
-
